Rep. April McClain Delaney Sells Bio-Techne Corp (NASDAQ:TECH) Stock

Key Points

• Rep. April McClain Delaney sold between $1,001 and $15,000 of Bio‑Techne (NASDAQ:TECH) stock on March 26, a transaction disclosed on April 6.
• She also made multiple purchases of $1,001–$15,000 stakes in other companies between March 16–31, 2026, including Entegris, Somnigroup International, Rollins, Tractor Supply and Nasdaq.
• Bio‑Techne recently beat quarterly EPS estimates, has a market cap of about $8.64 billion and a 0.6% dividend yield, and carries a consensus analyst rating of "Moderate Buy" with a $72.77 target price.

Representative April McClain Delaney (Democratic-Maryland) recently sold shares of Bio-Techne Corp NASDAQ: TECH. In a filing disclosed on April 06th, the Representative disclosed that they had sold between $1,001 and $15,000 in Bio-Techne stock on March 26th.

Representative April McClain Delaney also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Entegris NASDAQ: ENTG on 3/31/2026.
• Purchased $1,001 - $15,000 in shares of Somnigroup International NYSE: SGI on 3/31/2026.
• Purchased $1,001 - $15,000 in shares of Rollins NYSE: ROL on 3/31/2026.
• Purchased $1,001 - $15,000 in shares of Tractor Supply NASDAQ: TSCO on 3/31/2026.
• Purchased $1,001 - $15,000 in shares of Nasdaq NASDAQ: NDAQ on 3/31/2026.
• Purchased $1,001 - $15,000 in shares of Packaging Corporation of America NYSE: PKG on 3/20/2026.
• Purchased $1,001 - $15,000 in shares of Nasdaq NASDAQ: NDAQ on 3/18/2026.
• Purchased $1,001 - $15,000 in shares of Packaging Corporation of America NYSE: PKG on 3/17/2026.
• Purchased $1,001 - $15,000 in shares of Somnigroup International NYSE: SGI on 3/16/2026.
• Purchased $1,001 - $15,000 in shares of Tractor Supply NASDAQ: TSCO on 3/16/2026.

Bio-Techne Trading Up 2.6%

NASDAQ TECH opened at $55.21 on Thursday. Bio-Techne Corp has a fifty-two week low of $46.01 and a fifty-two week high of $72.16. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.08 and a current ratio of 4.54. The stock has a 50 day simple moving average of $56.81 and a two-hundred day simple moving average of $59.79. The stock has a market cap of $8.64 billion, a P/E ratio of 108.26, a price-to-earnings-growth ratio of 3.49 and a beta of 1.49.

Bio-Techne (NASDAQ:TECH - Get Free Report) last released its quarterly earnings data on Wednesday, February 4th. The biotechnology company reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.03. Bio-Techne had a return on equity of 13.94% and a net margin of 6.67%.The business had revenue of $295.88 million during the quarter, compared to analysts' expectations of $290.20 million. During the same quarter last year, the business posted $0.42 EPS. The business's revenue was down .4% on a year-over-year basis. On average, analysts forecast that Bio-Techne Corp will post 1.67 earnings per share for the current year.

Bio-Techne Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, February 27th. Shareholders of record on Monday, February 16th were issued a $0.08 dividend. The ex-dividend date was Friday, February 13th. This represents a $0.32 annualized dividend and a yield of 0.6%. Bio-Techne's dividend payout ratio (DPR) is 62.75%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TECH. Asset Management One Co. Ltd. increased its position in Bio-Techne by 2.7% during the 4th quarter. Asset Management One Co. Ltd. now owns 5,752 shares of the biotechnology company's stock valued at $341,000 after buying an additional 153 shares in the last quarter. Accredited Investors Inc. increased its position in Bio-Techne by 2.7% during the 4th quarter. Accredited Investors Inc. now owns 6,052 shares of the biotechnology company's stock valued at $356,000 after buying an additional 161 shares in the last quarter. Oak Thistle LLC increased its position in Bio-Techne by 1.9% during the 3rd quarter. Oak Thistle LLC now owns 9,314 shares of the biotechnology company's stock valued at $518,000 after buying an additional 173 shares in the last quarter. Allworth Financial LP increased its position in Bio-Techne by 28.4% during the 3rd quarter. Allworth Financial LP now owns 786 shares of the biotechnology company's stock valued at $44,000 after buying an additional 174 shares in the last quarter. Finally, Oppenheimer & Co. Inc. increased its position in Bio-Techne by 3.5% during the 4th quarter. Oppenheimer & Co. Inc. now owns 5,351 shares of the biotechnology company's stock valued at $315,000 after buying an additional 181 shares in the last quarter. Hedge funds and other institutional investors own 98.95% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on TECH shares. Weiss Ratings cut Bio-Techne from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, March 27th. Wells Fargo & Company increased their price objective on Bio-Techne from $70.00 to $76.00 and gave the stock an "overweight" rating in a report on Friday, February 6th. Robert W. Baird set a $70.00 price objective on Bio-Techne in a report on Thursday, February 5th. TD Cowen reiterated a "buy" rating on shares of Bio-Techne in a report on Tuesday, March 17th. Finally, Deutsche Bank Aktiengesellschaft set a $72.00 price objective on Bio-Techne and gave the stock a "buy" rating in a report on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $72.77.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland's 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland's 6th Congressional District. She declared candidacy for the 2026 election. April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor's degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Bio-Techne Company Profile

Bio-Techne Corporation NASDAQ: TECH is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.